Vertically integrated, multi-state cannabis company Curaleaf Holdings Inc CURLF said Friday morning it addressed issues the U.S. Food and Drug Administration raised in a letter related to its CBD product marketing.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
What Happened
The FDA sent an open "warning letter" to Curaleaf on Monday stating the company is making illegal or false claims on its website and social media accounts related to benefits of CBD usage. The company said Friday it immediately undertook a review of its website and social media platforms to remove all statements the FDA deemed to be non-compliant.
The company also confirmed with the FDA several of the products highlighted in the letter had previously been discontinued.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
Why It's Important
Curaleaf CEO Joseph Lusardi said the cannabis industry "needs, wants and appreciates" the FDA's role in ensuring regulation and compliance in the CBD market.
"Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve," he said.
Curaleaf affirmed its intention in the press release to "work diligently" to make sure all information it provides to consumers are in complete compliant with FDA requirements.
Curaleaf's stock traded around $7.45 per share at time of publication.
Related Links:
Curaleaf Trades Lower After FDA Sends Warning On CBD Products
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
